A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

NCT02086175 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

Interventions

DRUG: Imprime PGG
DRUG: Rituximab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]